Meeting report on the Alzheimer’s Drug Discovery Foundation 14th International Conference on Alzheimer’s Drug Discovery

Lauren G Friedman,Penny A Dacks,Rachel F Lane,Diana W Shineman,Katherine Price,Aaron J Carman,Howard M Fillit

doi:10.1186/alzrt252

Abstract

The Alzheimer’s Drug Discovery Foundation’s 14th International Conference on Alzheimer’s Drug Discovery was held on 9 and 10 September in Jersey City, NJ, USA. This annual meeting highlights novel therapeutic approaches supported by the Alzheimer’s Drug Discovery Foundation in development for Alzheimer’s disease and related dementias.

Highlights

Alzheimer’s disease (AD) is a complex, multifactorial disease with an urgent need for effective, disease-modifying treatments
Researchers continue to make progress on promising targets that contribute to mitochondrial dysfunction, altered lipid and cholesterol metabolism, neuroinflammation, and synaptic dysfunction
DNA sequencing of blood collected from centenarians with preserved cognitive function identified coding variants in insulin growth factor-1 and cholesteryl ester transfer protein, reinforcing the contribution of both metabolism and cholesterol homeostasis to cognitive function

Summary

Introduction

Alzheimer’s disease (AD) is a complex, multifactorial disease with an urgent need for effective, disease-modifying treatments. Presenters at the 2013 International Conference on Alzheimer’s Drug Discovery emphasized diverse preclinical and clinical therapeutic approaches. * Correspondence: RLane@alzdiscovery.org 3Alzheimer’s Drug Discovery Foundation, 57 West 57th Street, Suite 904, New York, NY 10019, USA Full list of author information is available at the end of the article diseases to the treatment of AD.

Results

Conclusion